Host: Charles Turck, PharmD, BCPS, BCCCP

Guest: Jerome Goldschmidt, MD

Despite the potential benefits of biosimilars, such as decreased costs for patients, healthcare systems, and payers,1,2 their uptake in U.S. clinical practice has lagged behind that of the E.U.2 That’s why Dr. Jerome Goldschmidt joins Dr. Charles Turck to address common misconceptions surrounding biosimilars and examine key points in their development, manufacturing, and approval process. Dr. Goldschmidt is a medical oncology specialist practicing at Blue Ridge Cancer Care, and he’s also affiliated with the U.S. Oncology Network in Blacksburg, Virginia.

References:
1. IQVIA. Biosimilars in the United States 2023–2027: Competition, Savings, and Sustainability. 2023. Accessed June 20, 2023. https://www.iqvia.com/insights/the-iqvia-institute/reports/biosimilars-in-the-united-states-2023-2027
2. Kvien TK, Patel K, Strand V. The cost savings of biosimilars can help increase patient access and lift the financial burden of health care systems. Semin Arthritis Rheum. 2022;52:151939. doi:10.1016/j.semarthrit.2021.11.009

©2023 Amgen Inc. All rights reserved. USA-CBU-81658 8/23